New study seeks safer dosing for cancer drug in patients with liver issues

NCT ID NCT07036133

First seen Feb 17, 2026 · Last updated May 09, 2026 · Updated 10 times

Summary

This study looks at how the body processes the cancer drug pralatrexate in people with advanced solid tumors or blood cancers who also have mild, moderate, or severe liver problems. Researchers will measure drug levels in the blood and track side effects to find the safest dose. The goal is to provide dosing guidance for patients with liver impairment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Gabrail Cancer Center

    RECRUITING

    Canton, Ohio, 44718, United States

    Contact

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

    Contact

  • Northwestern University - Feinberg School of Medicine

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact

  • TOI Clinical Research

    WITHDRAWN

    Cerritos, California, 90703, United States

Conditions

Explore the condition pages connected to this study.